NasdaqCM - Nasdaq Real Time Price USD
Molecular Templates, Inc. (MTEM)
At close: October 22 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
23,484.0000
52,625.0000
19,754.0000
38,697.0000
15,635.0000
--
Operating Expense
42,338.0000
63,091.0000
108,625.0000
118,771.0000
116,477.0000
--
Operating Income
-18,854.0000
-10,466.0000
-88,871.0000
-80,074.0000
-100,842.0000
--
Net Non Operating Interest Income Expense
488.0000
-1,446.0000
-3,728.0000
-2,935.0000
-677.0000
--
Other Income Expense
2,729.0000
3,777.0000
-66.0000
--
-3,392.0000
-22,120.0000
Pretax Income
-15,637.0000
-8,135.0000
-92,665.0000
-83,009.0000
-104,911.0000
--
Tax Provision
26.0000
-11.0000
53.0000
--
5.0000
--
Net Income Common Stockholders
-15,626.0000
-8,124.0000
-92,718.0000
-83,009.0000
-104,916.0000
--
Diluted NI Available to Com Stockholders
-15,626.0000
-8,124.0000
-92,718.0000
-83,009.0000
-104,916.0000
--
Basic EPS
-3.05
-1.80
-24.75
-22.50
-33.00
--
Diluted EPS
-3.05
-1.80
-24.75
-22.50
-33.00
--
Basic Average Shares
5,605.7410
4,501.2060
3,755.6300
3,686.5190
3,173.5500
--
Diluted Average Shares
5,605.7410
4,501.2060
3,755.6300
3,686.5190
3,173.5500
--
Total Operating Income as Reported
-18,854.0000
-10,466.0000
-88,871.0000
-80,074.0000
-100,842.0000
--
Total Expenses
42,338.0000
63,091.0000
108,625.0000
118,771.0000
116,477.0000
--
Net Income from Continuing & Discontinued Operation
-15,626.0000
-8,124.0000
-92,718.0000
-83,009.0000
-104,916.0000
--
Normalized Income
-18,355.0000
-11,895.8928
-92,665.8600
-83,009.0000
-102,439.8400
--
Interest Income
627.0000
1,208.0000
988.0000
434.0000
1,028.0000
--
Interest Expense
139.0000
2,654.0000
4,716.0000
3,369.0000
1,705.0000
--
Net Interest Income
488.0000
-1,446.0000
-3,728.0000
-2,935.0000
-677.0000
--
EBIT
-15,498.0000
-5,481.0000
-87,949.0000
-79,640.0000
-103,206.0000
--
EBITDA
-10,625.0000
1,164.0000
-80,566.0000
-73,010.0000
-99,289.0000
--
Reconciled Depreciation
4,873.0000
6,645.0000
7,383.0000
6,630.0000
3,917.0000
--
Net Income from Continuing Operation Net Minority Interest
-15,626.0000
-8,124.0000
-92,718.0000
-83,009.0000
-104,916.0000
--
Total Unusual Items Excluding Goodwill
2,729.0000
3,777.0000
-66.0000
--
-3,392.0000
--
Total Unusual Items
2,729.0000
3,777.0000
-66.0000
--
-3,392.0000
--
Normalized EBITDA
-13,354.0000
-2,613.0000
-80,500.0000
-73,010.0000
-95,897.0000
--
Tax Rate for Calcs
--
0.0000
0.0002
--
0.0003
--
Tax Effect of Unusual Items
--
5.1072
-13.8600
--
-915.8400
--
12/31/2019 - 2/4/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NTBL Notable Labs, Ltd.
0.2479
-27.68%
TVGN Tevogen Bio Holdings Inc.
1.6100
-10.56%
GRI GRI Bio, Inc.
0.9700
-26.52%
BDRX Biodexa Pharmaceuticals Plc
6.24
+4.35%
APVO Aptevo Therapeutics Inc.
0.3536
+48.01%
ADTX Aditxt, Inc.
1.0200
-6.42%
QNRX Quoin Pharmaceuticals, Ltd.
0.7519
-13.03%
WINT Windtree Therapeutics, Inc.
0.8959
-16.27%
GNPX Genprex, Inc.
3.5900
+137.75%
TPST Tempest Therapeutics, Inc.
1.0500
0.00%